Please use this identifier to cite or link to this item:
Title: A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Austin Authors: Wong, S F;Gan, Hui K ;Cher, Lawrence M 
Affiliation: Department of Medical Oncology, Austin Health, 145 Studley Road, Melbourne, Victoria 3084, Australia
Issue Date: 17-Sep-2012
Publication information: Journal of Clinical Neuroscience 2012; 19(11): 1501-5
Abstract: Primary central nervous system lymphoma (PCNSL) is a rare form of extra-nodal non-Hodgkin lymphoma. Although recommendations for first-line treatment usually incorporate high-dose methotrexate, there is substantial heterogeneity in the types of salvage therapies used at relapse. Phase II data supported the use of temozolomide as a well-tolerated treatment modality in this setting. Therefore, we reviewed the treatment and outcomes of patients with relapsed PCNSL who were treated with salvage temozolomide at our institution. Seven patients were treated with salvage temozolomide between January 2000 and May 2011. The objective response rate was 14%. Progression-free survival was 2 months (95% confidence interval [CI]: 0-5.9) and median overall survival was 4 months (95% CI: 0-13). Toxicity was mild, with one episode of grade 3 neutropenia during 25 cycles of chemotherapy. Although these results are consistent with previous phase II results, the outcomes for these patients remain extremely poor. The low toxicity of temozolomide raises the possibility of combining temozolomide with other chemotherapeutic agents or targeted agents in future clinical trials.
Gov't Doc #: 22995759
DOI: 10.1016/j.jocn.2012.04.001
Type: Journal Article
Subjects: Adult
Antineoplastic Agents, Alkylating.therapeutic use
Central Nervous System Neoplasms.drug therapy.pathology
Dacarbazine.analogs & derivatives.therapeutic use
Disease-Free Survival
Kaplan-Meier Estimate
Lymphoma.drug therapy.pathology
Middle Aged
Neoplasm Recurrence, Local.drug therapy
Salvage Therapy
Survival Analysis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.